BioPharma Resources

Drug Trial Radar · NCT07219940

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

An Open-label and Dose-escalation Phase I Clinical Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of HLA-G-targeted Exosome (SOB100) in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Lead sponsor
Shine-On Biomedical Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.

Conditions

  • Healthy Subjects
  • Exosome
  • Targeted Therapy

Interventions

  • SOB100Drug

    Drug: SOB100 Participants will receive SOB100 and evaluate the safety and tolerability of SOB100 during the dose escalation phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse event (AE)Time frame: From start until 3 weeks after the last dose of SOB100
  2. Incidence of serious adverse event (SAE)Time frame: From start until 3 weeks after the last dose of SOB100
  3. Incidence of treatment-emergent adverse event (TEAE)Time frame: From start until 3 weeks after the last dose of SOB100
  4. Abnormalities in physical examination (PE)Time frame: From start until 3 weeks after the last dose of SOB100
  5. Abnormalities in ECGTime frame: From start until 3 weeks after the last dose of SOB100

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel International - Baltimore Early Phase Clinical Unit

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.